TrialCritical care (London, England)2022

Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem.

Marin H Kollef et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.